WO2012011906A1 - Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina - Google Patents

Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina Download PDF

Info

Publication number
WO2012011906A1
WO2012011906A1 PCT/US2010/042857 US2010042857W WO2012011906A1 WO 2012011906 A1 WO2012011906 A1 WO 2012011906A1 US 2010042857 W US2010042857 W US 2010042857W WO 2012011906 A1 WO2012011906 A1 WO 2012011906A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
area
tyrosinase
skin surface
laminaria saccharina
Prior art date
Application number
PCT/US2010/042857
Other languages
English (en)
Inventor
Cheri Lynn Swanson
Tomohiro Hakozaki
Leo Timothy Ii Laughlin
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to PCT/US2010/042857 priority Critical patent/WO2012011906A1/fr
Priority to EP10737440.7A priority patent/EP2595600A1/fr
Publication of WO2012011906A1 publication Critical patent/WO2012011906A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]

Definitions

  • the present invention relates to methods for inhibiting tyrosinase activity by using an extract of Laminaria Saccharina.
  • Melanin is produced by a complex set of reactions within the melanocyte involving, at a basic level, the enzyme tyrosinase and the protein L-tyrosine. It is well recognized that tyrosinase is an essential component of melanin synthesis. Tyrosinase catalyzes the conversion of L-tyrosine to DOPA (L-3,4-dihydroxyphenylalanine) and of DOPA to dopaquinone. Dopaquinone undergoes further conversion to form melanin. A need exists for novel methods and compositions by which to inhibit tyrosinase activity.
  • DOPA L-3,4-dihydroxyphenylalanine
  • Extracts of Laminaria Saccharina a species of brown algae
  • Phlorogine Phlorogine is known as anti-seborrhoeic agent that can regulate the activity of sebaceous glands, as described for example in United States Patent Application Publication No. 2008/0119527A1.
  • Extraction methods for brown algae are also known.
  • European Patent No. 1074262B1 describes an extraction method for the class Phaeophyceae and the species Laminaria Ochroleuca. These extracts are described as being used in cosmetic compositions as an osmoprotector, free-radical scavenger, or against the effects of skin aging effects.
  • a cosmetic composition sold under the brand name SK-II Facial Clear Solution has a concentration of Phlorogine of about 1.25%.
  • the SK-II Facial Clear Solution is marketed as a gel hydrator that moisturizes the skin without increasing oily shine.
  • a method of inhibiting tyrosinase activity comprising the step of applying a composition comprising a Laminaria Saccharina extract to a substrate in need of tyrosinase inhibition.
  • a method of inhibiting tyrosinase activity of a skin surface comprising the steps of identifying a substrate in need of tyrosinase inhibition, wherein the substrate is an area on the skin surface; and applying a composition comprising a Laminaria Saccharina extract to the area, wherein the composition comprises 0.025% or less of a Laminaria Saccharina extract.
  • a method of inhibiting tyrosinase activity of a facial skin surface comprising the steps of selecting an area on the facial skin surface in need of tyrosinase inhibition, wherein the area is a hyperpigmented spot, applying a composition comprising a Laminaria Saccharina extract to the area, wherein the composition comprises 0.025% or less of a Laminaria Saccharina extract, and leaving the composition on the area for at least about 1 hour.
  • the present invention may take other forms. Further forms of the present invention will be appreciated from the detailed description that follows.
  • compositions of the present invention can comprise, consist essentially of, or consist of, the essential components as well as optional ingredients described herein.
  • “consisting essentially of” means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.
  • applying means to place a composition of the present invention into contact with a suitable substrate.
  • compositions or components described are suitable for use in contact with human skin tissue without undue toxicity, incompatibility, instability, allergic response, and the like.
  • safe and effective amount means an amount of a compound or composition sufficient to significantly induce a positive benefit.
  • post-inflammatory hyperpigmentation refers to an acute or temporary increase in pigmentation as a response to a transient inflammatory event, especially in dark skin subjects. Post-inflammatory hyperpigmentation typically subsides once the transient inflammatory event dissipates. Examples of transient inflammatory events include, but are not limited to, acne lesions, ingrown hairs, scratches, insect bites, surfactant damage, and short-term UV exposure.
  • hyperpigmented spot refers to a defined area of skin wherein the pigmentation is greater than that of an adjacent area of skin due to localized and chronic or systemic overproduction of melanin.
  • Hyperpigmented spots can include one or more of age spots, sun spots, solar lentigos, hypo-melanotic lesions, freckles, and melasma spots.
  • age spots refers to a defined area of skin wherein the pigmentation is greater than that of adjacent skin due to localized and chronic overproduction of melanin caused by intrinsic or extrinsic aging factors.
  • skin tone agent refers to an agent that regulates melanin production signals, synthesis of melanin, systemic transfer of melanin between the melanocyte and the keratinocyte, and/or melanin degradation.
  • Skin tone agents can improve the appearance of uneven skin tone by acting as a lightening or pigmentation reduction cosmetic agent. Skin tone agents can be identified using biochemical assays, cell based assays, skin based ex-vivo assays, and/or en vivo testing.
  • skin tone refers to the overall appearance of melanin in the skin caused by the systemic, rather than transient, synthesis of melanin. Skin tone is typically characterized over a larger area of the skin. The area ideally may be than 100 mm 2 , but larger areas are envisioned such as the entirety of the facial skin or any of the facial skin surfaces. Skin tone can be measured by image analysis. For example, overall lightness can be measured by L* coordinate in L*a*b* color space (International Commission on Illumination). Chromophore mapping such as melanin mapping may be used as an indicator of overall skin tone. Mean melanin may be calculated from the chromophore map data. Additionally, skin ton evenness can be determined by melanin evenness which also may be determined calculated from the chromophore map data. Suitable chromophore mapping techniques are discussed in the example below.
  • facial skin surfaces refers to one or more of forehead, periorbital, cheek, perioral, chin, and nose skin surfaces.
  • compositions of the present invention include a safe and effective amount of Laminaria Saccharina extract, a brown algae extract.
  • the compositions of the present invention may comprise Laminaria Saccharina extract in any amount allowing for reasonable delivery of the composition to a substrate. Surprisingly, it has been found that small quantities of Laminaria Saccharina extract provide appreciable tyrosinase inhibition effect.
  • the compositions of the present invention may comprise Laminaria Saccharina extract in amounts less than about
  • compositions of the present invention may comprise Laminaria Saccharina extract in amounts greater than about 0.00125%, 0.0025%, 0.005%, or 0.01%.
  • the delineated upper and lower range limits are interchangeable to create ranges not explicitly disclosed.
  • the Laminaria Saccharina extract can be prepared by processes known in the art, such as, for example, described in European Patent No. 1074262B1.
  • a suitable Laminaria Saccharina extract containing composition is commercially available as Phlorogine and/or Phlorogine BG, from Marine Biotech, France. Phlorogine and/or Phlorogine BG contain approximately about 1% to about 2.5% dry Laminaria Saccharina extract with the remaining material being inert carrier. Another suitable Laminaria Saccharina extract is available via product code HG 657 from Ennagram, France. Other suitable compositions may be formed by combining Laminaria Saccharina extract (such as Phlorogine or Phlorogine BG) with additional materials.
  • the Laminaria Saccharina extract containing composition may further comprise a dermatologically acceptable carrier, a tone agent, an antiinflammatory, a sunscreen active, and/or other actives and agents as described below.
  • compositions of the present invention may also comprise a dermatologically acceptable carrier ("carrier”) for the composition.
  • carrier dermatologically acceptable carrier
  • the carrier is present at a level of from about 50% to about 99%, about 60% to about 98%, about 70% to about 98%, or, alternatively, from about 80% to about 95%, by weight of the composition.
  • the carrier can be in a wide variety of forms. Non- limiting examples include simple solutions (aqueous or oil based), emulsions, and solid forms (gels, sticks, flowable solids, amorphous materials).
  • the dermatologically acceptable carrier is in the form of an emulsion.
  • Emulsion may be generally classified as having a continuous aqueous phase (e.g. , oil-in- water and water-in-oil-in-water) or a continuous oil phase (e.g. , water-in-oil and oil-in-water-in-oil).
  • the oil phase of the present invention may comprise silicone oils, non- silicone oils such as hydrocarbon oils, esters, ethers, and the like, and mixtures thereof.
  • the aqueous phase typically comprises water.
  • the aqueous phase may comprise components other than water (non-water components), including but not limited to water-soluble moisturizing agents, conditioning agents, anti-microbials, humectants and/or other water-soluble skin care actives.
  • the non-water component of the composition comprises a humectant such as glycerin and/or other polyols.
  • the composition may be substantially (i.e. , less than 1% water) or fully anhydrous.
  • a suitable carrier is selected to yield a desired product form.
  • the solubility or dispersibility of the compositions components may dictate the form and composition of the carrier.
  • oil-in- water or water-in-oil emulsions are preferred.
  • Emulsions may further comprise an emulsifier.
  • the composition may comprise any suitable percentage of emulsifier to sufficiently emulsify the carrier. Suitable weight ranges include from about 0.1% to about 10% or about 0.2% to about 5% of an emulsifier, based on the weight of the composition.
  • Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are disclosed in, for example, U.S. Patent 3,755,560, U.S. Patent 4,421,769, and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986). Suitable emulsions may have a wide range of viscosities, depending on the desired product form.
  • the carrier may further comprise a thickening agent as are well known in the art to provide compositions having a suitable viscosity and rheological character.
  • the compositions of the present invention may be included to further improve overall skin tone.
  • the compositions of the present invention contain up to about 50%, 40%, 30%, 20%. 10%. 5%, or 3%, by weight of the composition, of the skin tone agent.
  • the compositions of the present invention contain at least about 0.001%, 0.01%, 0.1%, 0.2%, 0.5%, or 1%, by weight of the composition, of the skin tone agent. Suitable ranges include any combination of the lower and upper limits including suitable ranges from about 0.1% to about 50%; from about 0.2% to about 20%; or from about 1% to about 10%, by weight of the composition, of the skin tone agent.
  • the amounts listed herein are only to be used as a guide, as the optimum amount of the skin tone agent will depend on the specific active selected since their potency does vary considerably.
  • Suitable skin tone agents include, but are not limited to, sugar amines, vitamin B3 compounds, arbutin, deoxyarbutin, sucrose dilaurante, bakuchoil (4-[(lE, 3S)-3-ethenyl-3,7- dimethyl - 1,6 octadienyl] phenol or monterpene phenol), pyrenoine (available from Biotech Marine, France), panicum miliaceum seed extract, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid (i.e., undecenoic acid), zinc undecylenate, thiamine (Vitamin Bl) and its hydrochloride, L- tryptophan, hexylrescorcinol, helianthus annuus (sunflower) and vitis vinifera (grape) leaf
  • the skin tone agent is selected from vitamin B3 compounds, sugar amines, hexamidine compounds, salicylic acid, and retinoids.
  • vitamin B3 compound means a compound having the formula:
  • R is - CONH2 (i.e., niacinamide), - COOH (i.e. , nicotinic acid) or - ⁇ 3 ⁇ 40 ⁇ (i.e., nicotinyl alcohol); derivatives thereof; and salts of any of the foregoing.
  • sucgar amine includes isomers and tautomers of such and its salts (e.g. , HC1 salt) and its derivatives.
  • sugar amines examples include glucosamine, N-acetyl glucosamine, mannosamine, N-acetyl mannosamine, galactosamine, N-acetyl galactosamine, their isomers (e.g., stereoisomers), and their salts (e.g. , HC1 salt).
  • hexaminide compound means a compound having the formula:
  • hexamidine compound includes hexamidine diisethionate.
  • Hyperpigmentation may result from skin inflammation.
  • Transient inflammatory events triggering hyperpigmentation and, more specifically, post-inflammatory hyperpigmentation include, but are not limited to, acne lesions, ingrown hairs, scratches, insect bites, surfactant damage, and short-term UV exposure.
  • Inflammation induced hyperpigmentation including postinflammatory hyperpigmentation may be managed by incorporating into the compositions of the present invention an anti-inflammatory agent.
  • the compositions of the present invention contain up to about 20%. 10%. 5%, 3%, or 1% by weight of the composition, of the anti-inflammatory agent.
  • compositions of the present invention contain at least about 0.001%, 0.01%, 0.1%, 0.2%, 0.3% 0.5%, or 1%, by weight of the composition, of the anti-inflammatory agent. Suitable ranges include any combination of the lower and upper limits.
  • Suitable anti-inflammatory agents include, but are not limited to nonsteroidal anti-inflammatory agents (NSAIDS including but not limited to ibuprofen, naproxen, flufenamic acid, etofenamate, aspirin, mefenamic acid, meclofenamic acid, piroxicam and felbinac), glycyrrhizic acid (also known as glycyrrhizin, glycyrrhixinic acid, and glycyrrhetinic acid glycoside) and salts such as dipotassium glycyrrhizate, glycyrrhetenic acid, licorice extracts, bisabolol (e.g., alpha bisabolol), manjistha (extracted from plants in the genus Rubia, particularly Rubia cordifolia), and guggal (extracted from plants in the genus Commiphora, particularly Commiphora mukul), kol
  • compositions of the subject invention may comprise one or more sunscreen actives (or sunscreen agents) and/or ultraviolet light absorbers.
  • sunscreen active includes both sunscreen agents and physical sunblocks. Sunscreen actives and ultraviolet light absorbers may be organic or inorganic.
  • sunscreen actives and ultraviolet light absorbers are disclosed in Personal Care Product Council's International Cosmetic Ingredient Dictionary and Handbook, Thirteenth Edition, as "sunscreen agents.”
  • Particularly suitable sunscreen actives are 2-ethylhexyl-p-methoxycinnamate (commercially available as PARSOLTM MCX), 4,4'-t-butyl methoxydibenzoyl-methane (commercially available as PARSOLTM 1789), 2- hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digalloyltrioleate, 2,2- dihydroxy-4-methoxybenzophenone, ethyl-4-(bis(hydroxypropyl))aminobenzoate, 2-ethylhexyl- 2-cyano-3,3-diphenylacrylate, 2-ethylhexyl-salicylate, glyceryl-p-aminobenzoate, 3,3,5-tri- methylcycl
  • the composition may comprise from about 1% to about 20%, and alternatively from about 2% to about 10% by weight of the composition, of the sunscreen active and/or ultraviolet light absorber. Exact amounts will vary depending upon the chosen sunscreen active and/or ultraviolet light absorber and the desired Sun Protection Factor (SPF), and are within the knowledge and judgment of one of skill in the art.
  • SPF Sun Protection Factor
  • compositions of the present invention may contain a variety of other ingredients that are conventionally used in given product types provided that they do not unacceptably alter the benefits of the invention.
  • compositions of the present invention may contain from about 0.0001% to about 50%; from about 0.001% to about 20%; or, alternately, from about 0.01% to about 10%, by weight of the composition, of the other actives and agents.
  • the amounts listed herein are only to be used as a guide, as the optimum amount of the optional components used in a composition will depend on the specific active selected since their potency does vary considerably. Hence, the amount of some actives and agents useful in the present invention may be outside the ranges listed herein.
  • compositions of the present invention may include optional actives and agents such as anti-acne actives, desquamation actives, anti-cellulite agents, chelating agents, flavonoids, tanning active, non-vitamin antioxidants and radical scavengers, hair growth regulators, anti-wrinkle actives, anti-atrophy actives, minerals, phytosterols and/or plant hormones, N-acyl amino acid compounds, antimicrobial or antifungal actives, and other useful skin care actives, which are described in further detail in U.S. application publication No. US2006/0275237A1 and US2004/0175347A1.
  • these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, anti-caking agents, antifoaming agents, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, and thickeners.
  • abrasives absorb
  • compositions of the present invention are non-limiting examples of the compositions of the present invention.
  • the examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention, which would be recognized by one of ordinary skill in the art.
  • all concentrations are listed as weight percent, unless otherwise specified and may exclude minor materials such as diluents, filler, and so forth.
  • the listed formulations therefore, comprise the listed components and any minor materials associated with such components. As is apparent to one of ordinary skill in the art, the selection of these minor materials will vary depending on the physical and chemical characteristics of the particular ingredients selected to make the present invention as described herein.
  • compositions of the present invention are generally prepared by conventional methods such as are known in the art of making compositions and topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like. Typically, emulsions are prepared by first mixing the aqueous phase materials separately from the fatty phase materials and then combining the two phases as appropriate to yield the desired continuous phase. The compositions are preferably prepared such as to optimize stability (physical stability, chemical stability, photostability) and/or delivery of the active materials.
  • This optimization may include appropriate pH (e.g., less than 7), exclusion of materials that can complex with the active agent and thus negatively impact stability or delivery (e.g., exclusion of contaminating iron), use of approaches to prevent complex formation (e.g., appropriate dispersing agents or dual compartment packaging), use of appropriate photostability approaches (e.g., incorporation of sunscreen/sunblock, use of opaque packaging), etc.
  • appropriate pH e.g., less than 7
  • exclusion of materials that can complex with the active agent and thus negatively impact stability or delivery e.g., exclusion of contaminating iron
  • approaches to prevent complex formation e.g., appropriate dispersing agents or dual compartment packaging
  • use of appropriate photostability approaches e.g., incorporation of sunscreen/sunblock, use of opaque packaging
  • Methods of inhibiting tyrosinase activity may involve application of the aforementioned composition.
  • the composition may be applied to a substrate in need of tyrosinase inhibition.
  • Suitable substrates in need of tyrosinase inhibition may be selected or indentified as part of the method.
  • the substrate in need of tyrosinase inhibition includes any substrate containing tyrosinase which an individual selects for inhibition.
  • the substrate may be a simple solution such as the phosphate buffered saline solution used in the Tyrosinase Inhibition Assay described below.
  • the substrate may be a plant or animal tissue.
  • the substrate is a skin surface.
  • a suitable skin surfaces include facial skin surfaces, hand and arm skin surfaces, foot and leg skin surfaces, and neck and chest skin surfaces (e.g. , decolletage).
  • a particular area or areas of the skin surface may be selected for tyrosinase inhibition.
  • the area may be the facial skin surface including the forehead, perioral, chin, periorbital, nose, and/or cheek.
  • the area on the skin surface is a hyperpigmented spot or other area with increased melanin production.
  • the hyperpigmented spot may be identified by the user or a third party such as a dermatologist, cosmetician, or other caregiver. Identification may be done by visual inspection of the skin for hyperpigmented spots in need of treatment based on size and/or color. Identification may also be done by commercially available imaging devices such SIAscope ® V (available from Astron Clinica, Ltd., UK) or the VISIA ® Complexion Analysis system (available from Canfield Scientific, Inc., Fairfield, NJ). Both devices are capable of collecting images of the skin and identifying hyperpigmented spots. In some instances, the method comprises the step of identifying a plurality of hyperpigmented spots.
  • the composition may be applied and left on the substrate for a sufficient contact time and/or repeatedly applied a sufficient number of times to achieve the desired inhibition of tyrosinase.
  • the contact time is greater than about 1 hour, 2 hours, 6 hours, 8 hours, 12 hours, or 24 hours.
  • the contact time is time from application of the composition until the composition is removed.
  • the composition may be removed by rinsing or washing the substrate. When a skin surface is selected as the substrate, the composition may be removed by washing or rinsing the skin.
  • the treatment period may involve a single application or multiple applications.
  • the composition may be applied at least daily. In other embodiments, the composition is applied at least twice daily. Multiple applications may occur over the course of at least about 1 week. Alternately, the treatment period may last more than about 4 weeks or more than about 8 weeks. In certain embodiments, the treatment period will extend over multiple months (i.e., 3-12 months) or multiple years.
  • This assay can identify agents that may interfere with the ability of mushroom tyrosinase enzyme to convert L-tyrosine to L-dihydroxyphenylalanine (L-DOPA).
  • Mushroom Tyrosinase available from Sigma-Aldrich, Missouri, USA (item T3824), is employed in the assay.
  • the substrate solution may include a lx concentrated phosphate buffered saline (PBS) (pH 7.4), available from Invitrogen, California, USA (GIBCO catalogue number 10010-023).
  • PBS lx concentrated phosphate buffered saline
  • a positive control may be employed utilizing 4-Hydroxyphenyl- -D-glucopyranoside (Arbutin), available from Sigma-Aldrich, Missouri, USA.
  • the assay also uses dimethyl sulfoxide (DSMO), available from Sigma-Aldrich, Missouri, USA, (item D5879), and Falcon® 1172 MicrotestTM non-tissue culture treated, clear, flat bottom 96 well plates.
  • Tyrosinase Inhibitor is determined by a UV- Visible Spectrum Plate Reader, such as a SpectraMax250, available from Molecular Devices, California, USA, coupled with data acquisition and analysis software such as SoftMax Pro, available from Molecular Devices, California, USA.
  • the assay steps include:
  • Phlorogine Test Compound - Phlorogine is diluted in sufficient water to yield needed concentrations. Final volume of test compound in the assay is 2 ⁇ , so working solutions are typically made up at 5-40mM (100X), which yields a final concentration of 50 - 400 ⁇ in the assay.
  • Tyrosinase Enzyme - Reconstitute tyrosinase enzyme at 1000 U/mL with cold IX PBS buffer. Store this stock solution in ImL aliquots protected from light at -20°C until needed. Enzyme working solution of 26 U/mL is prepared by adding ImL thawed stock solution (1000 U/ml) to 37.5 mL cold IX PBS buffer. This is enough enzyme for four 96-well plates. Protect from light and keep on ice until used in the assay.
  • Phlorogine inhibited tyrosinase activity as shown in Table 1 below.

Abstract

L'invention concerne un procédé permettant d'inhiber l'activité de la tyrosinase qui peut impliquer l'application d'une composition comprenant un extrait de laminaria saccharina à un substrat qui requiert l'inhibition de la tyrosinase. Le procédé peut en outre comprendre l'étape d'identification d'un substrat nécessitant l'inhibition de la tyrosinase. Ladite composition peut être laissée sur le substrat et/ou appliquée de manière répétée au substrat afin d'obtenir l'inhibition souhaitée de l'activité de la tyrosinase.
PCT/US2010/042857 2010-07-22 2010-07-22 Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina WO2012011906A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2010/042857 WO2012011906A1 (fr) 2010-07-22 2010-07-22 Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina
EP10737440.7A EP2595600A1 (fr) 2010-07-22 2010-07-22 Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/042857 WO2012011906A1 (fr) 2010-07-22 2010-07-22 Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina

Publications (1)

Publication Number Publication Date
WO2012011906A1 true WO2012011906A1 (fr) 2012-01-26

Family

ID=43087068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/042857 WO2012011906A1 (fr) 2010-07-22 2010-07-22 Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina

Country Status (2)

Country Link
EP (1) EP2595600A1 (fr)
WO (1) WO2012011906A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
WO1998026755A1 (fr) * 1996-12-18 1998-06-25 Lancaster Group Gmbh Preparation cosmetique de soins et de toilette contenant des extraits de plantes et d'algues
FR2838340A1 (fr) * 2002-04-10 2003-10-17 Gelyma Utilisation d'un extrait d'algue brune dans les domaines cosmetique et dermatologique
US20040175347A1 (en) 2003-03-04 2004-09-09 The Procter & Gamble Company Regulation of mammalian keratinous tissue using hexamidine compositions
EP1074262B1 (fr) 1999-08-03 2005-04-20 Secma Biotechnologies Marines Extrait d'algues Laminaria, procédé de préparation et compositions cosmétiques ou pharmaceutiques le contenant
US20060275237A1 (en) 2005-05-09 2006-12-07 Bissett Donald L Skin care compositions containing idebenone
US20080119527A1 (en) 2006-09-15 2008-05-22 L'oreal Composition for combating the localized hyperpigmentation of dark skin
EP1997537A2 (fr) * 2007-05-23 2008-12-03 Coty Prestige Lancaster Group GmbH Produit cosmétique de nettoyage de la peau
WO2009089880A1 (fr) * 2008-01-17 2009-07-23 Merck Patent Gmbh Préparation contenant des dérivés de chroman-2-one
WO2010088225A2 (fr) * 2009-01-29 2010-08-05 The Procter & Gamble Company Régulation des tissus kératiniens de mammifères à l'aide de produits actifs pour la peau et/ou le cheveu

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755560A (en) 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
WO1998026755A1 (fr) * 1996-12-18 1998-06-25 Lancaster Group Gmbh Preparation cosmetique de soins et de toilette contenant des extraits de plantes et d'algues
EP1074262B1 (fr) 1999-08-03 2005-04-20 Secma Biotechnologies Marines Extrait d'algues Laminaria, procédé de préparation et compositions cosmétiques ou pharmaceutiques le contenant
FR2838340A1 (fr) * 2002-04-10 2003-10-17 Gelyma Utilisation d'un extrait d'algue brune dans les domaines cosmetique et dermatologique
US20040175347A1 (en) 2003-03-04 2004-09-09 The Procter & Gamble Company Regulation of mammalian keratinous tissue using hexamidine compositions
US20060275237A1 (en) 2005-05-09 2006-12-07 Bissett Donald L Skin care compositions containing idebenone
US20080119527A1 (en) 2006-09-15 2008-05-22 L'oreal Composition for combating the localized hyperpigmentation of dark skin
EP1997537A2 (fr) * 2007-05-23 2008-12-03 Coty Prestige Lancaster Group GmbH Produit cosmétique de nettoyage de la peau
WO2009089880A1 (fr) * 2008-01-17 2009-07-23 Merck Patent Gmbh Préparation contenant des dérivés de chroman-2-one
WO2010088225A2 (fr) * 2009-01-29 2010-08-05 The Procter & Gamble Company Régulation des tissus kératiniens de mammifères à l'aide de produits actifs pour la peau et/ou le cheveu

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"International Cosmetic Ingredient Dictionary and Handbook, 11th Edition", 2006, THE COSMETICS, TOILTERY & FRAGRANCE ASSOCIATION, Washington, USA, ISBN: 1-882621-34-4, article "Laminaria Saccharina Extract", XP002610983 *
DATABASE GNPD [online] Mintel; April 2008 (2008-04-01), "Extra Concentrated Brightening Essence", XP002610976, Database accession no. 887317 *

Also Published As

Publication number Publication date
EP2595600A1 (fr) 2013-05-29

Similar Documents

Publication Publication Date Title
US20160317431A1 (en) Methods of inhibiting par2 activation of keratinocytes and methods of making compositions therefor
CA2804917C (fr) Procedes permettant d'ameliorer l'aspect d'une ou de zones hyperpigmentees au moyen d'un extrait de laminaria saccharina
EP2442784B1 (fr) Compositions et procédés permettant d'inhiber l'activation de par2 dans les kératinocytes
US20130022557A1 (en) Methods For Improving the Appearance of Hyperpigmented Spot(s) Using an Extract of Laminaria Saccharina
EP2613763B1 (fr) Compositions cosmétiques comprenant une fraction de ficus serum et procédés pour réduire l'aspect hyperpigmenté de la peau
AU2016265959A1 (en) Bioactive compositions comprising Ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation
US10543165B2 (en) Method of improving the appearance of aging skin
WO2012011905A1 (fr) Procédé d'amélioration de l'apparence de taches hyperpigmentées impliquant plusieurs principes actifs
US8673372B2 (en) Methods for improving the appearance of hyperpigmented skin using a synergistic composition comprising banyan tree, lotus, and clover serum fractions
AU2017203699B2 (en) Composition comprising banyan tree, lotus, and clover serum fractions (hyperpigmentation)
US20130022559A1 (en) Methods For Inhibiting Tyrosinase Using an Extract of Laminaria Saccharina
WO2012011906A1 (fr) Procédés d'inhibition de la tyrosinase au moyen d'un extrait de laminaria saccharina
US20130022558A1 (en) Methods For Imrproving the Appearance of Hyperpigmented Spot(s) and Skin Tone
WO2012011907A1 (fr) Extrait de laminaria saccharina et vitamine b3 comme agents de blanchiment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10737440

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010737440

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE